gastritis
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Aged between 18 and 65 years; 2. No gender limit; 3. Clinical symptoms are typical symptoms of acute gastritis such as upper abdominal pain, fullness, nausea, vomiting and loss of appetite; 4. The patient was diagnosed with acute aggravation of acute gastritis/chronic gastritis by endoscopy combined with symptoms and medical history; 5. Consent to investigational treatment options; 6. Voluntarily sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with a history of peptic ulcer or reflux esophagitis; 2. Patients with a history of gastrointestinal surgery; 3. Patients with a history of gastrointestinal malignancy; 4. Used drugs that affected the study, such as PPIs, H2RA, mucosal protector, etc., within 2 weeks before entering the study; 5. Patients who required glucocorticoids, NSAIDs, or antithrombotic drugs during the study period; 6. Helicobacter pylori positive patients; 7. Pregnant or lactating patients; 8. Women of childbearing age who do not use contraception; 9. Patients with serious diseases of the blood system, liver, kidney, heart, lung, hematopoietic system and endocrine system; 10. Patients with contraindications for lafurtidine or rebapide; 11. Patients taking drugs that may interact with each other; 12. Patients with mental illness or addicted to alcohol and drugs; 13. Patients who are participating in other clinical studies; 14. Patients with communication and coordination disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gastric mucosa; | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement of symptoms (upper abdominal pain, bloating, acid reflux, heartburn, belching, nausea/vomiting, loss of appetite) after 14 days of medication; | — |
Countries
China
Contacts
Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology